What is the UK and international evidence and impact behind in-silico technologies based?
InSilicoUK Innovation Network
By 2025 at least £2.6 billion worth of Pharma and Med Devices underpinned by in-silico methods will be made in the UK, even at our current share of the global manufacturing.
In-silico technologies will be critical to the future of the 111,200 directly employed in 2010 UK manufacturing sites in the Pharmaceutical and Med-Tech sectors.
Medical Device Innovation Consortium
Computational modeling and simulation (CM&S) has numerous applications throughout the medical device life cycle, from product development and testing to clinical evaluation, premarket submissions, and postmarket performance assessment and failure analysis. CM&S has the potential to reduce or eliminate the need for physical prototyping and testing, and to rapidly and cost-effectively evaluate more design and clinical use variations than are feasible using traditional methods.cuments
Modelling & Simulation WG, FDA’s Office of the ,
Elucidates how and where M&S is used across FDA, and the type and purpose of M&S used
Presents a selection of M&S case studies from across nearly all FDA centers, which demonstrate how M&S is playing a tangible role in FDA fulfilling its mission
Identifies opportunities for FDA to better harness M&S in upcoming years by embracing computational advances and new (and big) data streams to develop improved public health solutions
Government Office for Science
Council for Science and Technology
This report, known also as Blackett Review, sets out the findings of a review looking at the rapid evolution of UK computational modelling capability, and how it could be better used in both the public and private sectors.
We use cookies to improve your experience and to help us understand how you use our site. Please refer to our cookie notice and privacy statement for more information regarding cookies and other third-party tracking that may be enabled.